Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusAlternative strategies for proof-of-principle studies of antibacterial agentsMethicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odysseyNewer antibacterial drugs for a new century.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensEfficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium sppTissue penetration of telavancin after intravenous administration in healthy subjects.Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 studyTelavancin: a new lipoglycopeptide with multiple mechanisms of action.Current and novel antibiotics against resistant Gram-positive bacteriaEfficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureusTelavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).Role of linezolid in the treatment of complicated skin and soft tissue infections.Telavancin: a novel lipoglycopeptide for serious gram-positive infections.Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbitsEmergence and management of drug-resistant enterococcal infections.Vancomycin resistance: are there better glycopeptides coming?Telavancin: a novel lipoglycopeptide antibiotic.Transplacental transfer of vancomycin and telavancinA comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Resistant pathogen-associated skin and skin-structure infections: antibiotic options.Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults.History and evolution of antibiotic resistance in coagulase-negative staphylococci: Susceptibility profiles of new anti-staphylococcal agents.In vitro activity of telavancin against resistant gram-positive bacteria.Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters.Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infectionIn vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women.
P2860
Q24556635-BB806AA9-77B6-4726-B6DE-23BC4214D0F9Q26850895-082ACCAE-73A4-42B9-9D35-ABA62E531EC5Q28235095-05BFD81A-39F4-4BD4-9FC2-C962C3BBDDDAQ30433333-BA18D984-DE29-450A-B1E3-0ECB0705ACF6Q33788308-3110C1AB-AB6C-447D-A66B-C27D8B5A71F4Q34077052-B8D6924B-41B1-4CB5-8C30-CDA5E06FFFA9Q34141027-C3B3ED0C-8985-41D8-AD42-94186844AC2FQ34352132-83E7BDE3-2644-4AAB-B1A8-C3973AB86D0CQ34509652-D0C7AE90-15A4-40DD-ACF5-F1DE805CF1D2Q34572923-62FC64C0-6A82-4C7F-B357-3114C81343A9Q35026521-4AE02034-1ECD-4D7C-BD5B-9E3E8D1D5882Q35879100-E77D692E-6730-46D9-88AC-50B6DE99EA2AQ35905561-032513BA-A925-4497-A463-0760C4D5A684Q36505478-228E9E01-5218-42FC-925A-0D0D38350062Q36736356-2530E002-258F-40E7-9F61-49F9DB816F27Q36744770-6606DAF4-08AE-430F-8A2C-634E29EB0FB2Q37071199-7AB3D46D-01D5-4F1D-9385-F9967176F47FQ37077627-28B29B85-A570-4969-A27F-D61CC4A4457BQ37117865-15C3727C-AA31-43E2-8B5E-CA9327D95B13Q37204180-6AA902B6-1BFA-4E30-ACED-3AA5C1219824Q37291346-6D53465F-0BAA-47EE-9B44-05899DBD1C8FQ37340562-5F03288B-3149-45B6-B055-A3774FE1733EQ37463589-B69A9731-EFBA-4B38-8F37-208E4343DC6EQ37478888-844FCBB6-9E53-4134-B258-00C2D82F65F5Q37661510-33ED92B9-B84C-4ACC-A042-F8BABCD9D7A2Q37785546-3604D2C5-7F1C-4C71-814F-450142C35684Q37955286-234CB721-2DCA-41C6-98C1-AAC889900DD7Q38048845-512E2EB0-B3A6-4C3E-B091-200DA0B3D000Q38084726-7B9A052D-30EE-4B4F-BF83-A3AAD3EFF00CQ38536137-5CAFEB53-493E-42CB-8C9E-47D9538E8C80Q39686121-F169A68C-D8D1-4E1A-9359-335CBCE0BAB8Q41807543-01394EDA-0656-4222-A1B0-23A333F85902Q41814975-C7C6E47C-83E3-4114-A9E4-C721E0E2F7B3Q41831644-1F577472-1973-4F45-8D2A-5EC47018CE60Q41925060-25224740-B9C4-4E61-A75B-8C9026840BF9Q41950850-DA5B8D01-7AF5-45BC-A2C8-7D430D7B3C40Q41999444-DE20EF09-6DA1-4AE0-AD50-E5BA1F252EAAQ42788454-206F5BC9-BBCA-4F14-A332-EE89A5408795Q43184655-0E219ACC-9687-4FC2-A0E3-0D03B7FDF05CQ44935039-47118160-1453-4EF1-9EC7-5D25471A8933
P2860
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Comparative in vitro activity ...... gainst Gram-positive bacteria.
@en
Comparative in vitro activity ...... gainst Gram-positive bacteria.
@nl
type
label
Comparative in vitro activity ...... gainst Gram-positive bacteria.
@en
Comparative in vitro activity ...... gainst Gram-positive bacteria.
@nl
prefLabel
Comparative in vitro activity ...... gainst Gram-positive bacteria.
@en
Comparative in vitro activity ...... gainst Gram-positive bacteria.
@nl
P2093
P356
P1476
Comparative in vitro activity ...... gainst Gram-positive bacteria.
@en
P2093
Ian Phillips
Koné Kaniga
P304
P356
10.1093/JAC/DKH156
P407
P577
2004-03-17T00:00:00Z